Modern medicine has provided many cancer drugs with life-saving capabilities, but often toxic effects on healthy cells and resulting side effects stop them from reaching their full potential.

An iron-binding drug that is already approved for treatment of other diseases could provide a novel way to attack ovarian tumors, according to a new study led by Weill Cornell Medicine researchers.

In human cell tests, these bisphosphonates successfully bound to excess iron, reducing oxidative stress and preventing cell damage. The study offers a potential safer alternative to current iron ...